LB Pharmaceuticals Inc Common Stock Stock Analysis & AI Score
LB Pharmaceuticals Inc Common Stock (LBRX) has an ST Score of 62.3 (B), driven by its Financial Strength (A) and held back by its Growth (C+). Analysts rate it Buy with a $51.86 price target (+37.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
LB Pharmaceuticals Inc Common Stock (LBRX) has an ST Score of 62.3 (B), driven by its Financial Strength (A) and held back by its Growth (C+). Analysts rate it Buy with a $51.86 price target (+37.2% upside).
- Strongest
- Financial StrengthA
- Weakest
- GrowthC+
All factor grades
- Financial StrengthA
- ValuationA-
- ProfitabilityB+
- MomentumB+
- ForecastB
- GrowthC+
- Piotroski2/9
Contact
LBRX stock: frequently asked questions
What is LBRX's ST Score?
LB Pharmaceuticals Inc Common Stock (LBRX) has an ST Score of 62.3 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LBRX a buy, hold, or sell?
Analysts rate LBRX a Buy, with a price target of $51.86 (+37.2% vs the current price). Our ST Score grades it B (62.3/100). The ST Score is a data-driven signal, not a recommendation.
What are LBRX's factor grades?
Valuation A-, Profitability B+, Financial Strength A, Momentum B+, Growth C+, Forecast B.
What is LBRX's valuation grade?
LB Pharmaceuticals Inc Common Stock (LBRX) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LBRX's growth grade?
LB Pharmaceuticals Inc Common Stock (LBRX) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LBRX's profitability grade?
LB Pharmaceuticals Inc Common Stock (LBRX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LBRX's financial strength grade?
LB Pharmaceuticals Inc Common Stock (LBRX) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LBRX?
The average analyst price target for LB Pharmaceuticals Inc Common Stock (LBRX) is $51.86 from 3 analysts, which is +37.2% versus the recent price of $37.80.
What is LBRX's Piotroski score?
LB Pharmaceuticals Inc Common Stock (LBRX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.